On March 17, 2022, Dr. Tan Yongcai's team from the Oncology Department of Jinshazhou Hospital of Guangzhou University of Chinese Medicine successfully completed liver malignant tumor ablation treatment for two patients using the latest Nanoknife tumor ablation technology guided by CT puncture. The surgery used the High Voltage Pulse Minimally Invasive Therapeutic System independently developed and produced by Shanghai Yuanshan Medical Technology Co., Ltd. (hereinafter referred to as "Alpmed").
Case 1: Patient female, 70 years old, malignant tumor of the liver with a lesion located close to the intestine.
Case 2: Patient female, 33 years old, malignant tumor of the liver, the left liver was resected, and the lesion was located inferiorly adjacent to the inferior vena cava and right adjacent to the abdominal aorta.
（Case 1 preoperative enhanced CT images） （Case 1 preoperative needle placement planning）
The surgery was performed under general anesthesia on the patient, using percutaneous puncture and double-needle wrapping of the lesion, followed by ablation. During the ablation process, the field strength was stable and the current increased significantly, and the ablation was successful.
"Postoperative enhanced CT imaging shows clear boundaries of the lesion and no significant enhancement in the ablation area. This ablation surgery was very successful, and we will continue to follow up with the patient's recovery within one month after the surgery," said Director Tan Yongcai.
（Case 1 Intraoperative CT-guided precise puncture of tumor lesion）（Case 1 immediate postoperative CT scan image） （Three-day postoperative review of enhanced CT images）
After the operation, Director Tan Yongcai said: these two patients' tumors are close to large blood vessels and intestines, so it is difficult to get better efficacy using other methods and have many complications, while using Nanoknife ablation can get better efficacy with significantly less side effects. Compared with other ablation techniques, tumors close to large blood vessels, diaphragm, gastrointestinal tract, bile duct, gallbladder, pancreas, heart and other high-risk areas are more advantageous and suitable for Nanoknife ablation. The domestic Nanoknife can selectively ablate using its characteristic advantageous technology, which effectively protects the important tissues around the lesion, and is very suitable for patients with refractory and complicated liver malignancies, and will continue to do more clinical case exploration in the future.
|
Tan Yongcai
Jinshazhou Hospital of Guangzhou University of Chinese Medicine Oncology Ward 7 Department Head Former Head of Minimally Invasive Tumor Intervention, Southern War Zone Air Force Hospital Member of World Association of Tumor Intervention Member of Minimally Invasive Intervention Committee of Guangdong Association of Integrative Medicine Standing member of Minimally Invasive Intervention Committee of Guangdong Primary Medicine Association He is in charge of the department and leads the minimally invasive interventional team to carry out in-depth technical cooperation and scientific research with the nationally renowned minimally invasive interventional experts from the Affiliated Cancer Hospital of Sun Yat-sen University, Guangdong Provincial People's Hospital, the First and Third Hospitals of Sun Yat-sen University, etc. He is specialized in minimally invasive interventional techniques for solid tumors (embolization and chemotherapy, arterial perfusion, microwave, radiofrequency ablation, cryoablation, nanoablation, nanoablation, etc.). He specializes in minimally invasive interventional techniques for solid tumors (embolization chemotherapy, arterial perfusion, microwave ablation, radiofrequency ablation, cryoablation, Nanoknife ablation, biliary drainage, biliary stent implantation, etc.), especially in the treatment of primary liver cancer HAIC, and is skilled in the comprehensive treatment of liver and lung metastases. He has studied in the Cancer Hospital of Sun Yat-sen University for many years. During more than ten years of minimally invasive intervention in tumor, he has treated more than 10,000 tumor patients and performed more than 5,000 operations personally and more than 3,000 operations jointly with renowned experts. He has brought good news to many advanced cancer patients, and his patients are all over the country and have received numerous banners. He has participated in many scientific research projects and published many academic papers. |
Membership
